Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor's First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for Oncology

/PRNewswire/ -- On December 23, Regor Therapeutics, a clinical-stage biotech company, announced authorization from the US Food and Drug Administration (FDA) to...

Related Keywords

China ,Shanghai ,Xiayang Qiu ,Jiangxi , ,Drug Administration ,Regor Therapeutics ,